At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of stomach or gastroesophageal junction with bulk of disease in stomach
- ✓Locally advanced disease meeting specific staging: Tany N+ M0 or T3-T4 Nany M0 (excluding T1-2N0M0)
- ✓Disease must be potentially curable by surgery without evidence of distant metastases
- ✓Karnofsky Performance Status ≥60% (ECOG ≤2)
- ✕Any metastatic disease (M1)
- ✕NYHA Class III or IV heart disease; history of myocardial infarction or active angina within 6 months
- ✕Grade 2 or greater pre-existing peripheral neuropathy
- ✕Clinically significant auditory impairment or hearing loss
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of Preoperative Chemotherapy With Irinotecan and Cisplatin for Advanced, But Resectable Gastric Cancer: A Coordinated Multidisciplinary, Multicenter Study Linking Functional Imaging, Genomic Expression Profiles and Histopathology
In Brief
A Phase 2 clinical trial evaluating Cisplatin, Computed Tomography, and 5 other interventions for Gastric Adenocarcinoma and 3 related conditions. Completed, enrolled 55 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them before surgery may shrink the tumor so that it can be removed during surgery.
Study Details
Timeline
Interventions
Given IV
Undergo FDG and FLT PET/CT
Undergo FDG-PET/CT
Undergo FLT-PET/CT
Given IV
Undergo FDG and FLT PET/CT
Undergo radical subtotal or total gastrectomy with lymph node dissection